Media releases

CHMP issues positive opinion to extend Invokana® (canagliflozin) indication to reflect improved renal outcomes in patients with diabetic kidney disease and type 2 diabetes

29 May 2020

STRICTLY FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY

Statement from Mundipharma on COVID-19

15 May 2020

Nyxoid and Mundipharma

18 Dec 2019

FOR EUROPEAN BUSINESS/TRADE MEDIA ONLY

Mundipharma presents wealth of data for Penthrox®▼(methoxyflurane) at EUSEM Congress, demonstrating superiority compared to standard of care in trauma pain in adults

15 Oct 2019

FOR EUROPEAN MEDICAL AND TRADE MEDIA ONLY

Swissmedic reviewing licence extension for the SGLT2 inhibitor Invokana® (canagliflozin) in fast-track procedure

10 Oct 2019

STRICTLY FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY

Cidara Therapeutics and Mundipharma Form Strategic Partnership to Develop and Commercialize Rezafungin

3 Sep 2019

Mundipharma Welcomes the New Guidelines from ESC/EASD Recommending First-Line use of Sodium-Glucose Co-transporter-2 Inhibitors for Type 2 Diabetes Patients with Cardiovascular Disease

3 Sep 2019

STRICTLY FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY

Mundipharma Announces the Licence Extension Submission for Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin) to the European Medicines Agency

22 Aug 2019

FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA

Mundipharma announces exclusive license and supply agreement with Prestige Biopharma for Tuznue® (HD201)

2 Jul 2019

FOR EUROPEAN BUSINESS/TRADE MEDIA ONLY

Invokana® (canagliflozin) Significantly Reduced Major Cardiovascular Events and Kidney Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in New CREDENCE Analysis

11 Jun 2019

STRICTLY FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY

1 2